Protagonist Therapeutics Inc (PTGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.94 Million) by net assets ($645.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Protagonist Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PTGX total liabilities for a breakdown of total debt and financial obligations.
Protagonist Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagonist Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OHB SE
XETRA:OHB
|
-0.052x |
|
ShenZhen YUTO Packaging Technology Co Ltd
SHE:002831
|
0.052x |
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
0.132x |
|
ServiceTitan, Inc. Class A Common Stock
NASDAQ:TTAN
|
26.606x |
|
Imeik Technology Development Co
SHE:300896
|
0.032x |
|
COSCO SHIPPING Holdings Co. Ltd
F:C6G
|
0.025x |
|
Macy’s Inc
NYSE:M
|
0.243x |
|
SIGMASTAR TECH LTD
SHE:301536
|
0.014x |
Annual Cash Flow Conversion Efficiency for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Protagonist Therapeutics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Protagonist Therapeutics Inc (PTGX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $675.29 Million | $184.15 Million | 0.273x | +230.72% |
| 2023-12-31 | $336.68 Million | $-70.24 Million | -0.209x | +58.41% |
| 2022-12-31 | $215.61 Million | $-108.14 Million | -0.502x | -39.50% |
| 2021-12-31 | $300.02 Million | $-107.86 Million | -0.360x | -38.69% |
| 2020-12-31 | $279.61 Million | $-72.48 Million | -0.259x | +50.08% |
| 2019-12-31 | $79.96 Million | $-41.53 Million | -0.519x | -16.99% |
| 2018-12-31 | $112.52 Million | $-49.95 Million | -0.444x | -1483.01% |
| 2017-12-31 | $120.63 Million | $3.87 Million | 0.032x | +109.38% |
| 2016-12-31 | $87.56 Million | $-29.97 Million | -0.342x | +77.16% |
| 2015-12-31 | $9.60 Million | $-14.38 Million | -1.499x | -54.01% |
| 2014-12-31 | $7.96 Million | $-7.74 Million | -0.973x | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more